Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents

References

1. 1.↵
   2. Hao D,
   3. Ai T,
   4. Goerner F, et al

   . MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 2012;36:1060–71 doi:10.1002/jmri.23725 pmid:23090917

   CrossRefPubMed
2. 2.↵
   2. Frenzel T,
   3. Lengsfeld P,
   4. Schirmer H, et al

   . Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol 2008;43:817–28 doi:10.1097/RLI.0b013e3181852171 pmid:19002053

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Tweedle MF,
   3. Wedeking P,
   4. Kumar K

   . Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30:372–80 doi:10.1097/00004424-199506000-00008 pmid:7490190

   CrossRefPubMed
4. 4.↵
   2. Kanda T,
   3. Ishii K,
   4. Kawaguchi H, et al

   . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

   CrossRefPubMed
5. 5.↵
   2. Murata N,
   3. Gonzalez-Cuyar LF,
   4. Murata K, et al

   . Macrocyclic and other non–group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 2016;51:447–53 doi:10.1097/RLI.0000000000000252 pmid:26863577

   CrossRefPubMed
6. 6.↵
   2. McDonald RJ,
   3. McDonald JS,
   4. Kallmes DF, et al

   . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

   CrossRefPubMed
7. 7.↵
   2. Kanda T,
   3. Osawa M,
   4. Oba H, et al

   . High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275:803–09 doi:10.1148/radiol.14140364 pmid:25633504

   CrossRefPubMed
8. 8.↵
   2. Quattrocchi CC,
   3. Mallio CA,
   4. Errante Y, et al

   . Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015;50:470–72 doi:10.1097/RLI.0000000000000154 pmid:25756685

   CrossRefPubMed
9. 9.↵
   2. Errante Y,
   3. Cirimele V,
   4. Mallio CA, et al

   . Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014;49:685–90 doi:10.1097/RLI.0000000000000072 pmid:24872007

   CrossRefPubMed
10. 10.↵
    2. Radbruch A,
    3. Weberling LD,
    4. Kieslich PJ, et al

    . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275:783–91 doi:10.1148/radiol.2015150337 pmid:25848905

    CrossRefPubMed
11. 11.↵
    2. Cao Y,
    3. Huang DQ,
    4. Shih G, et al

    . Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol 2016;206:414–19 doi:10.2214/AJR.15.15327 pmid:26700156

    CrossRefPubMed
12. 12.↵
    2. Weberling LD,
    3. Kieslich PJ,
    4. Kickingereder P, et al

    . Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol 2015;50:743–48 doi:10.1097/RLI.0000000000000206 pmid:26352749

    CrossRefPubMed
13. 13.↵
    2. Radbruch A,
    3. Weberling LD,
    4. Kieslich PJ, et al

    . Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 2016;51:683–90 doi:10.1097/RLI.0000000000000308 pmid:27495187

    CrossRefPubMed
14. 14.↵
    2. Ramalho J,
    3. Castillo M,
    4. AlObaidy M, et al

    . High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 2015;276:836–44 doi:10.1148/radiol.2015150872 pmid:26079490

    CrossRefPubMed
15. 15.↵
    2. Freedman MS,
    3. Bar-Or A,
    4. Oger J, et al

    ; MAESTRO-01 Investigators. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011;77:1551–60 doi:10.1212/WNL.0b013e318233b240 pmid:21975206

    CrossRefPubMed
16. 16.↵
    2. Adin ME,
    3. Kleinberg L,
    4. Vaidya D, et al

    . Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. AJNR Am J Neuroradiol 2015;36:1859–65 doi:10.3174/ajnr.A4378 pmid:26294649

    Abstract/FREE Full Text
17. 17.↵
    2. Flood TF,
    3. Stence NV,
    4. Maloney JA, et al

    . Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. Radiology 2017;282:222–28 doi:10.1148/radiol.2016160356 pmid:27467467

    CrossRefPubMed
18. 18.↵
    2. Hu HH,
    3. Pokorney A,
    4. Towbin RB, et al

    . Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams. Pediatr Radiol 2016;46:1590–98 doi:10.1007/s00247-016-3646-3 pmid:27282825

    CrossRefPubMed
19. 19.↵
    2. Ramalho J,
    3. Semelka RC,
    4. Ramalho M, et al

    . Gadolinium-based contrast agent accumulation and toxicity: an update. AJNR Am J Neuroradiol 2016;37:1192–98 doi:10.3174/ajnr.A4615 pmid:26659341

    Abstract/FREE Full Text
20. 20.↵
    2. Zhang Y,
    3. Cao Y,
    4. Shih GL, et al

    . Extent of signal hyperintensity on unenhanced T1-weighted brain MR images after more than 35 administrations of linear gadolinium-based contrast agents. Radiology 2017;282:516–25 doi:10.1148/radiol.2016152864 pmid:27513848

    CrossRefPubMed
21. 21.↵
    2. Radbruch A

    . Are some agents less likely to deposit gadolinium in the brain? Magn Reson Imaging 2016;34:1351–54 doi:10.1016/j.mri.2016.09.001 pmid:27629022

    CrossRefPubMed
22. 22.↵
    2. Jost G,
    3. Frenzel T,
    4. Lohrke J, et al

    . Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue. Eur Radiol 2017;27:2877–85 doi:10.1007/s00330-016-4654-2 pmid:27832312

    CrossRefPubMed
23. 23.↵
    2. Öner AY,
    3. Barutcu B,
    4. Aykol Ş, et al

    . Intrathecal contrast-enhanced magnetic resonance imaging-related brain signal changes: residual gadolinium deposition? Invest Radiol 2017;52:195–97 doi:10.1097/RLI.0000000000000327 pmid:27755154

    CrossRefPubMed
24. 24.↵
    2. Frenzel T,
    3. Apte C,
    4. Jost G, et al

    . Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. Invest Radiol 2017;52:396–404 doi:10.1097/RLI.0000000000000352 pmid:28125438

    CrossRefPubMed
25. 25.↵
    2. Gulani V,
    3. Calamante F,
    4. Shellock FG, et al

    ; International Society for Magnetic Resonance in Medicine. Chelated or dechelated gadolinium deposition: authors' reply. Lancet Neurol 2017;16:955–56 doi:10.1016/S1474-4422(17)30365-4 pmid:29165254

    CrossRefPubMed